Zachary Roberts
Chief Tech/Sci/R&D Officer bij ALLOGENE THERAPEUTICS, INC.
Vermogen: 2 M $ op 31-03-2024
Profiel
Zachary Roberts is currently the Chief Medical Officer & Executive Vice President at Allogene Therapeutics, Inc. He previously worked as the Director-Clinical Medical Research at Amgen, Inc. in 2015, the Vice President-Clinical Development at Kite Pharma, Inc. from 2018 to 2019, and the Chief Medical Officer at Instil Bio, Inc. from 2020 to 2022.
Dr. Roberts obtained his undergraduate degree from the University of Maryland and his doctorate from the University of Maryland School of Medicine.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 25-01-2024 | 515 253 ( 0.30% ) | 2 M $ | 31-03-2024 |
Actieve functies van Zachary Roberts
| Bedrijven | Functie | Begin |
|---|---|---|
| ALLOGENE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 03-01-2023 |
Eerdere bekende functies van Zachary Roberts
| Bedrijven | Functie | Einde |
|---|---|---|
| INSTIL BIO, INC. | Chief Tech/Sci/R&D Officer | 11-11-2022 |
| KITE PHARMA INC | Chief Tech/Sci/R&D Officer | 01-05-2019 |
| AMGEN INC. | Chief Tech/Sci/R&D Officer | 01-07-2015 |
Opleiding van Zachary Roberts
| University of Maryland | Undergraduate Degree |
| University of Maryland School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| ALLOGENE THERAPEUTICS, INC. | Health Technology |
| INSTIL BIO, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Kite Pharma, Inc.
 Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
